Who Supplies Glucosamine to India from ITALY

To import finished pharmaceutical formulations containing Glucosamine into India, the foreign manufacturer must obtain a Drug Import License from the Directorate General of Foreign Trade (DGFT). The product must be registered with the Central Drugs Standard Control Organisation (CDSCO) by submitting Form CT-20/40/41, which includes detailed product information, manufacturing processes, and quality control measures. The registration process typically takes 6 to 12 months, depending on the completeness of the application and compliance with regulatory requirements. For formulations under HS Code 30049099, the manufacturer must provide a No Objection Certificate (NOC) from the Ministry of Health and Family Welfare, ensuring the product's safety and efficacy. The registration is valid for five years, after which renewal is required.

Imported Glucosamine formulations must undergo quality testing at CDSCO-approved laboratories to ensure compliance with Indian Pharmacopoeia standards. Each batch requires a Certificate of Analysis (CoA) confirming the product's quality, purity, and potency. Stability data, adhering to ICH Zone IV guidelines, must be provided to demonstrate the product's shelf-life under Indian climatic conditions. Upon arrival, customs drug inspectors perform port inspections, including sampling and testing, to verify compliance with regulatory standards. If a batch fails quality testing, it may be rejected, destroyed, or re-exported, depending on the severity of the non-compliance.

Between 2024 and 2026, the CDSCO has implemented stricter regulations for importing finished pharmaceutical formulations, including Glucosamine products. The introduction of the Production Linked Incentive (PLI) scheme has incentivized domestic manufacturing, leading to a reduction in import dependency. Bilateral agreements between India and Italy have facilitated smoother trade relations, with mutual recognition of Good Manufacturing Practices (GMP) and streamlined approval processes for Italian pharmaceutical products.

India imports finished Glucosamine formulations primarily due to the demand for patented and branded products not manufactured domestically. Specific dosage forms, such as effervescent tablets and liquid formulations, are often sourced from international markets. Despite a growing domestic capacity, India remains dependent on imports to meet the diverse needs of its population. The market size for Glucosamine formulations in India is estimated at $50 million annually, with imports accounting for approximately 30% of the total market.

The Basic Customs Duty (BCD) for Glucosamine formulations under HS Code 30049099 is 10%. An Education Cess of 2% and a Secondary Higher Education Cess of 1% are applicable, totaling 3%. The Countervailing Duty (CVD) is 6%. The Social Welfare Surcharge (SWS) is 10%. The Integrated Goods and Services Tax (IGST) is 12%. Considering abatements and exemptions, the total landed duty percentage is approximately 17.10%.

Italy's pharmaceutical industry is renowned for its high-quality standards, innovative formulations, and adherence to international regulatory norms. Italian manufacturers offer unique Glucosamine formulations, such as effervescent tablets and liquid forms, which are not widely available from other suppliers. While countries like China, Germany, and the United States also export Glucosamine formulations to India, Italy's emphasis on quality and specialized products gives it a competitive edge. Italy's share in India's Glucosamine import market is approximately 5%.

India imports Glucosamine formulations from Italy due to the availability of patented and branded products not manufactured domestically. Italian manufacturers offer specialized dosage forms, such as effervescent tablets and liquid formulations, which cater to specific patient needs. The high quality and adherence to international standards by Italian producers make them a preferred choice for Indian importers seeking reliable and effective Glucosamine products.

Compared to other origins like China, Germany, and the United States, Italy offers Glucosamine formulations with superior quality, innovative dosage forms, and compliance with international regulatory standards. While Chinese products may be more cost-effective, they often lack the quality assurance and regulatory compliance that Italian products provide. German and U.S. products are also of high quality but may not offer the same specialized formulations available from Italy.

Relying solely on Italian suppliers for Glucosamine formulations poses risks such as supply chain disruptions, currency fluctuations, and potential regulatory changes. To mitigate these risks, Indian importers should consider dual-sourcing strategies, maintain adequate inventory levels, and establish strong relationships with multiple suppliers. Regular monitoring of the political and economic climate in Italy is also advisable to anticipate and manage potential disruptions.

1. 1Dual-Sourcing: Engage with multiple suppliers from different countries to reduce dependency on a single source.
2. 2Inventory Planning: Maintain buffer stocks to cushion against supply chain disruptions.
3. 3Payment Terms: Negotiate favorable payment terms, such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP), to manage financial risks.
4. 4Supplier Qualification: Conduct thorough due diligence on potential suppliers, including audits and assessments of their manufacturing facilities and quality control processes.
5. 5Regulatory Compliance: Ensure that all imported products comply with Indian regulatory standards and are registered with the CDSCO.

1. 1Obtain a Drug Import License from the DGFT.
2. 2Register the product with the CDSCO by submitting Form CT-20/40/41.
3. 3Provide a No Objection Certificate (NOC) from the Ministry of Health and Family Welfare.
4. 4Ensure compliance with Indian Pharmacopoeia standards.
5. 5Provide stability data adhering to ICH Zone IV guidelines.
6. 6Obtain a Certificate of Analysis (CoA) for each batch.
7. 7Ensure the product is registered with the CDSCO.

1. 1Certificate of Analysis (CoA) for each batch.
2. 2Certificate of Pharmaceutical Product (CoPP).
3. 3Good Manufacturing Practices (GMP) certificate.